Simon Jones
Directeur Financier/CFO chez Karus Therapeutics Ltd.
Profil
Simon Jones is currently working as a Director at OMERS Private Equity Europe Ltd.
and also holds positions at TH Global Ltd.
and Karus Therapeutics Ltd.
He previously worked as a Principal at Vodafone UK Ltd.
and as a Chief Financial Officer at Oxonica Ltd.
and Glide Pharmaceutical Technologies Ltd.
Mr. Jones completed his undergraduate degree at the University of Warwick.
Postes actifs de Simon Jones
Sociétés | Poste | Début |
---|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Directeur Financier/CFO | - |
OMERS Private Equity Europe Ltd. | Private Equity Investor | 01/03/2010 |
Anciens postes connus de Simon Jones
Sociétés | Poste | Fin |
---|---|---|
Oxonica Ltd.
Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Directeur Financier/CFO | - |
Vodafone UK Ltd.
Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Corporate Officer/Principal | - |
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Directeur Financier/CFO | 29/03/2013 |
Formation de Simon Jones
University of Warwick | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Glide Pharmaceutical Technologies Ltd.
Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
Oxonica Ltd.
Oxonica Ltd. Miscellaneous Commercial ServicesCommercial Services Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom. | Commercial Services |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Vodafone UK Ltd.
Vodafone UK Ltd. Wireless TelecommunicationsCommunications Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK. | Communications |
OMERS Private Equity Europe Ltd. | Finance |